Looking to transform your ADC target selection by identifying novel or repurposing already clinically validated targets to make best and first-in-class ADCs? Look no further than the 3rd ADC Target Selection Summit coming to Boston, MA this December🧪 As the ADC target space becomes increasingly saturates for well-understood clinically validated targets such as HER2 and TROP2, heads are now turning to identify novel targets amenable to ADCs and leverage improvements in linker-payload technologies to develop first-in-class or best-in-class ADCs. Sessions as part of the 3rd ADC Target Selection Summit include: 🧬Harnessing Target Specificity with Novel ADC Technology Advancements to Minimize Off-Target Toxicity 🧬Validating Novel ADC Targets for Progression into the Clinic 🧬Examining What Makes a Good ADC Target for Your Technology 🧬Optimizing Pairing of Target, Antibody & Linker-Payload Technologies 🧬Advancing Your Understanding of Target Biology to Aid in Target Selection Join expert speakers from AbbVie, Angiex Inc., AstraZeneca, Atreca, Inc., Bicycle Therapeutics, Bolt Biotherapeutics, Inc. , DynamiCure Biotechnology, Hillstream BioPharma, Iksuda Therapeutics, Innovent Biologics, Merck Group ., Seagen, Sutro Biopharma, Inc., ZielBio, Inc., and many more! Learn more here ---> https://ter.li/3xhd4f #worldadc #antibodydrugconjugates #targetselection #her2 #drugdevelopment #adc
